Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.
Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...
In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), ...
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering ...
Investor's Business Daily on MSN12h
Axon Earnings Beat; Taser Maker Arrests Stock's Stunning FallAxon posted Q4 results that topped analyst estimates on Tuesday afternoon. Axon stock initially surged after the report. The ...
Chegg faces challenges from Google AI, impacting traffic and revenue. Learn how Chegg plans to innovate with AI tools and ...
Andrew Dudum; Chairman of the Board, Chief Executive Officer; Hims & Hers Health Inc Oluyemi Okupe; Chief Financial Officer; Hims & Hers Health Inc Good afternoon, ladies and gentlemen, and thank you ...
The report raised fears about the sustainability of AI infrastructure growth. That could mean less demand for Nvidia's chips. TD Cowen's Michael Elias said his team's finding points to "a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback